# Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression

> **NCT00554398** · PHASE3 · COMPLETED · sponsor: **Germans Trias i Pujol Hospital** · enrollment: 69 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** MK-0518 400mg twice a day

## Key facts

- **NCT ID:** NCT00554398
- **Lead sponsor:** Germans Trias i Pujol Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-05
- **Final completion:** 2009-09
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2019-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554398, "Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00554398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*